pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT
Summit Therapeutics
Summit Therapeutics is a pharma organization headquartered in Miami, USA. It trades on NYSE under ticker SMMT. Primary therapeutic focus areas include Metastatic Colorectal Cancer, Duchenne Muscular Dystrophy, Non-Small
601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US HQ
2003 Founded
367 Employees
Public company Type
SMMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US
- Founded
- 2003
- Employees
- 367
- Programs
- 41
- Drugs
- 32
- Patents
- 20
Ivonescimab
Phase 2 · mab · Advanced Head and Neck Squamous Cell Carcinoma
Ivonescimab for Advanced Head and Neck Squamous Cell Carcinoma is a Phase 2 program (mab) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code UMCC 2025.012
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Summit Therapeutics
- Phase
- Phase 2
- Modality
- mab
- Indication
- Advanced Head and Neck Squamous Cell Carcinoma
- Status
- active
- Trials
- 1